BioAtla
(NASDAQ:BCAB)
$2.72
-0.11[-3.89%]
Last update: 11:59AM Get Real Time Here
Q1 2024 Earnings were released on Tue May 14th, after the market close
The most recent conference call was at 16:30 PM, 6 days ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

BioAtla Stock (NASDAQ:BCAB), Quotes and News Summary

BioAtla Stock (NASDAQ: BCAB) stock price, news, charts, stock research, profile.

Open$2.850
Close-
Volume / Avg.369.983K / 644.651K
Day Range2.655 - 2.865
52 Wk Range1.240 - 4.020
Market Cap$130.875M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
47
Short Interest
12.39%
Days to Cover9.99

Recent News

Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Avi Kapoor
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Lisa Levin
Dow Rises Over 100 Points; Rayonier Advanced Materials Shares Plunge
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday. The Dow traded up 0.40% to 33,653.27 while the NASDAQ rose 0.83% to 10,724.37. The S&P 500 also rose, gaining, 0.55% to 3,913.66.
Lisa Levin
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
0
0
0
0
Dec 23
1
Mar
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
BCAB
SYRS

FAQ

Q

How do I buy BioAtla (BCAB) stock?

A

You can purchase shares of BioAtla (NASDAQ: BCAB) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are BioAtla's (BCAB) competitors?

A

Other companies in BioAtla’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Molecular Partners (NASDAQ:MOLN), Renovaro (NASDAQ:RENB), CytomX Therapeutics (NASDAQ:CTMX) and Vistagen Therapeutics (NASDAQ:VTGN).

Q

What is the target price for BioAtla (BCAB) stock?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by HC Wainwright & Co. on Wednesday, May 15, 2024. The analyst firm set a price target for 7.00 expecting BCAB to rise to within 12 months (a possible 157.35% upside). 10 analyst firms have reported ratings in the last year.

Q

Current Stock Price for BioAtla (BCAB)?

A

The stock price for BioAtla (NASDAQ: BCAB) is $2.72 last updated Today at May 20, 2024 at 11:59 AM EDT.

Q

Does BioAtla (BCAB) pay a dividend?

A

There are no upcoming dividends for BioAtla.

Q

When is BioAtla (NASDAQ:BCAB) reporting earnings?

A

BioAtla’s Q2 earnings are confirmed for Tuesday, July 30, 2024.

Q

Is BioAtla (BCAB) going to split?

A

There is no upcoming split for BioAtla.

Q

What sector and industry does BioAtla (BCAB) operate in?

A

BioAtla is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch